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I. Abstract
Acute pancreatitis is a devastating inflammatory disease, which is initiated by the activation and
retention of digestive zymogens inside pancreatic acinar cells. It is proposed that adenosine
monophosphate-activated protein kinase (AMPK) regulates the early responses of acute
pancreatitis in pancreatic acinar cells (acini). A recent in vitro study shows that induction of
experimental pancreatitis in isolated rat pancreatic acini with supraphysiologic cerulein (an
orthologue of the hormone cholecystokinin) causes an increase in intracellular zymogen
activation, but a decrease in AMPK levels. Furthermore, in vitro pharmacologic stimulation of
AMPK reduces zymogen activation, having a protective effect. In this study, the effectiveness of
two AMPK activators was examined in two separate, clinically-relevant in vivo pancreatitis
models. In the first model, Sprague-Dawley rats received a pre-treatment of the AMPK activator
metformin via intraperitoneal (IP) injection. A second IP injection of cerulein was administered
one hour later. One hour following the second injection, the rat pancreata were harvested and
markers of pancreatitis were measured. Intracellular zymogen activation was assessed via trypsin
activity, edema was assessed via percentage wet weight, and extent of cellular damage was
assessed via histological staining. In the second model, C57/Bl6 mice received a pre-treatment of
either metformin or salicylate (also an AMPK activator). For each of the six hours following,
mice received an IP injection of cerulein. At the seventh hour, the pancreata were harvested. The
same parameters were assessed. In both models, the AMPK activators displayed a marked
decrease in intracellular zymogen activation. Edema data obtained through percentage wet
weight measurements were found to be insignificant. Histological staining of pre-treated sections
demonstrated a considerable decrease in edema and pyknotic nuclei in rats. These results
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strongly suggest that metformin and salicylate could potentially be used as prophylactic or
therapeutic treatments for patients early in the course of acute pancreatitis.
II. Introduction
Acute pancreatitis is described as a sudden inflammation of the pancreas. Pain and
swelling in a patient’s upper left side of the abdomen is often a strong indicator of the disease.
Other symptoms include nausea, vomiting, dehydration, and pain after food consumption.
Clinical signs used to make a diagnosis include a swollen abdomen, fever, rapid pulse, and high
amylase and lipase levels. Prognosis for acute pancreatitis ranges from mild to life-threatening,
depending on cause as well as risk factors. Approximately 210, 000 patients are hospitalized with
acute pancreatitis in the United States each year.[1] Treatment of this disease depends on both the
cause and the severity.
A pivotal step in the initiation of acute pancreatitis is the regulated conversion of
digestive zymogens, such as trypsinogen and chymotrypsinogen, to their active forms, trypsin
and chymotrypsin, and their retention within the pancreatic acinar cell. Subsequent studies have
demonstrated that additional pathologic acinar cell responses, including reduced apical secretion,
elaboration of inflammatory mediators, and development of a paracellular leak, are also observed
in the early phases of the disease.[2] Later responses include reduced perfusion, inflammation,
and cell death.
The pancreatic acinar cell has the highest average rate of protein synthesis in the body.[3]
This activity consumes high levels of ATP. Changes in acinar cell ATP levels have been reported
in experimental acute pancreatitis models and the extent of ATP depletion in acute pancreatitis
may correspond to disease severity. An important mechanism for energy sensing and
conservation is AMP-activated protein kinase (AMPK).[3] AMPK is known to conserve cellular
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energy by phosphorylating substrates to increase energy production or decrease activity of
processes with high-energy consumption. One study has reported that acinar cell ATP levels
change with pancreatitis stimuli, appearing to transiently increase, then fall.[4] Such fluctuations
in ATP can potentially modulate AMPK activity during acute pancreatitis.
AMPK is a heterotrimeric protein consisting of α, β, and γ subunits. The β and γ subunits
both function as regulatory domains. The α subunit, however, is the catalytic domain and serves
as the site of phosphorylation for AMPK. Specifically, phosphorylation occurs at the Thr172
residue of the α subunit.
A recent study performed by Shugrue et al. demonstrates the potential protective effect
AMPK has in the pancreatic acinar cell.[5] This study explored the pharmacological modulation
of AMPK and its effects on intracellular zymogen activation in cell culture. First, a group of
isolated rat pancreatic acinar cells was treated with a hyperstimulatory concentration of cerulein
(an orthologue of the hormone cholecystokinin), a substance commonly used to experimentally
induce pancreatitis. A second group of acinar cells was first pre-treated with agents that enhance
AMPK activity, namely AICAR and metformin. Then, the same hyperstimulatory dose of
cerulein was introduced to these pre-treated acinar cells to induce pancreatitis. By using trypsin
activity as a measure of intracellular zymogen activation, it was discovered that cells pre-treated
with AMPK activating drugs displayed a striking reduction of cerulein-induced zymogen
activation. This result was further supported through the pre-treatment of acinar cells with
Compound C, an AMPK inhibitor. As anticipated, Compound C produced the opposite effect of
AICAR and metformin; it increased cerulein-induced zymogen activation.[5]
Given that this rat in vitro model exhibited a decrease in zymogen activation, a rat in vivo
model was used to determine whether the effects of the AMPK activators would translate to
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decreased severity of acute pancreatitis. Although the rat model is a well-characterized model
that is useful for pancreatitis studies, the use of genetic knockout mice has been steadily
increasing over recent years. For this reason, a mouse model was also developed as a part of this
study. Attaining comparable results in mice could lay the foundation for transgenic studies.
The two AMPK activators used in this study are metformin and salicylate. Although
metformin and salicylate both activate AMPK, they do so using two completely different
mechanisms of action. Metformin works indirectly on AMPK by mildly reducing the activity of
the mitochondrial respiratory chain complex I.[6] The resulting decrease in ATP production puts
the cell into a hepatic energy state. In this state, the amount of AMP and ADP in the cell are
increased. The elevated AMP-to-ATP ratio causes the activation of AMPK. Salicylate, on the
other hand, has a direct effect on AMPK. After AMPK is phosphorylated at Thr172, salicylate
binds to the β subunit and acts as an allosteric activator.[7] The binding of salicylate also inhibits
certain phosphatases from dephosphorylating AMPK.
The results of this study provide evidence that pharmacological activation of AMPK in
both rats and mice causes a decrease in cerulein-induced zymogen activation, edema, and
cellular damage.

III. Methods
All experiments and procedures using animals were approved by the Veterans Affairs Healthcare
System’s Institutional Animal Care and Use Committee (IACUC) in West Haven, CT.
1a. In Vivo Rat Model. A 2-hour in vivo time-course was developed (Figure 1) whereby each
Sprague-Dawley rat was given one initial IP injection and an additional IP injection one hour
later. In the initial injection, each rat received either phosphate buffered saline (PBS control) or a
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pre-treatment of metformin (MET) (120mg/kg). In the second injection, each rat received either
PBS (control) or cerulein (40µg/kg). An hour following the second injection, the animals were
euthanized; their pancreata were harvested and used to assess the following parameters of
pancreatitis: intracellular zymogen activation, edema, and histological damage. This time-course
resulted in four separate treatment groups requiring a total of 16 rats (4 per treatment group):
1. PBS/PBS, 2. PBS/CER, 3. MET/PBS, 4. MET/CER. For simplicity, PBS/PBS will be
referred to as PBS, MET/PBS as MET, and PBS/CER as CER. MET/CER will still be referred
to as such.

1b. Zymogen Activation Assay. Following harvest of pancreatic tissue, samples were
homogenized in homogenization buffer [1.5 M Tris (pH 6.4), 0.3 M sucrose] and centrifuged at
600g (4°C) for 10 minutes. The post-nuclear supernatant (PNS) (containing zymogen granules)
of each sample was stored for assaying. For each sample, 10 µL of the PNS and 440 µL of
zymogen assay buffer [50 mM Tris (pH 8.1), 150 mM NaCl, 1 mM CaCl2, 0.01% BSA] were
both added to a well of a 24-well plate (Greiner Bio-one Cellstar TC-Plate). The assay was
initiated by the addition of 50 µL of 400 mM trypsin substrate (fluorometric trypsin substrate;
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Peptides International, Louisville, KY) diluted in zymogen assay buffer (40 mM final). The plate
was read using a fluorometric microtiter plate reader (model HTS 7000; Perkin-Elmer Analytical
Instruments, Shelton, CT. 380-nm excitation; 440-nm emission; 20 reads /10 min.).

1c. Edema. Following the harvest of pancreatic tissue, each sample was blotted and its
corresponding wet weight determined. The samples were then incubated at 60°C for 72 hours
and reweighed. Edema was expressed as percent wet weight using the following equation:
(Wet weight − Dry weight)/Wet weight × 100%. [8]

1d. Histological Assessment. A 1-millimeter piece of pancreatic tissue was removed from each
animal and was immersion fixed in 4% formalin. Then, the tissue was dehydrated, embedded in
paraffin, sectioned (5 µm), and stained with hematoxylin and eosin. Slides were viewed using an
Axiophot microscope (Carl Zeiss, Thornwood, NY) at 40x and 60x magnification and images
were collected with a Spot Digital camera (Diagnostic Instruments, Sterling Heights, MI).
Samples were assessed using a histological scoring system and representative images of each
treatment group were selected.

2a. In Vivo Mouse Model. A 7-hour in vivo time-course was developed (Figure 2) whereby each
C57/Bl6 (Wild type or Wt) mouse was given a single IP injection every hour for 7 hours. In the
initial injection, each mouse received either PBS control, a pre-treatment of MET (200mg/kg), or
a pre-treatment of salicylate (SAL) (120mg/kg). For each of the six hours following, each mouse
received either PBS (control) or CER (40µg/kg). At the seventh hour, the mice were euthanized;
their pancreata were harvested and used to assess the following parameters of pancreatitis:
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intracellular zymogen activation, edema, and histological damage. This time-course resulted in
six separate treatment groups: 1. PBS/PBS, 2. MET/PBS, 3. SAL/PBS, 4. PBS/CER 5.
MET/CER 6. SAL/CER. For simplicity, PBS/PBS will be referred to as PBS, MET/PBS as
MET, SAL/PBS as SAL, and PBS/CER as CER. MET/CER and SAL/CER will still be referred
to as such.

2b. Zymogen Activation Assay. See Section 3.1b for procedure.
2c. Edema. See Section 3.2c for procedure.
2d. Histological Assessment. See Section 3.2d for procedure.
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IV. Results
1a. Zymogen activation (Rat). Metformin pre-treatment of the rats was found to significantly
decrease cerulein-induced intracellular zymogen activation, as measured by trypsin activity
(Figure 3). Although the MET rats presented a slight decrease in trypsin activity in comparison
to PBS rats, this decrease was statistically insignificant.
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1b. Edema (Rat). CER rats exhibited significant amounts of edema in comparison to PBS
(control) rats (Figure 4). Specifically, CER rats had a percent wet weight of 80% whereas the
PBS rats had approximately 65%. MET/CER rats experienced a 5% reduction in edema at 75%
when compared to CER rats. The difference in edema between CER and MET/CER rats is
statistically insignificant. Since this measure of edema is limited to the wet weight of the
pancreas, histology was carefully examined to determine whether this result was conclusive.
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1c. Histology (Rat). Histological assessment of sections gathered from pancreatic tissue from
each of the four treatment groups is not consistent with the edema studies described above. It is
evident that unlike the CER sections, the MET/CER sections show a substantial decrease in
edema, pyknotic nuclei, and plasma membrane blebbing (Figure 5). PBS and MET are nearly
identical and exhibit no cellular damage, as expected. The visual evidence of cellular damage
(including edema) was found to be more reliable than the edema measurement carried out in
Section 4.1b.
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2a. Zymogen Activation (Mouse). Both metformin and salicylate pre-treatment of the rats were
found to decrease cerulein-induced intracellular zymogen activation, as measured by trypsin
activity (Figure 6). The two-fold decrease in trypsin activity between CER mice and SAL/CER
mice was determined to be statistically significant. However, the decrease in trypsin activity
between CER mice and MET/CER mice was found to only be approaching significance (p =
0.0553). Increasing the number of animals in the MET/CER treatment group might have
produced a statistically significant decrease.
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2b. Edema (Mouse). CER rats exhibited significant amounts of edema in comparison to PBS
(control) rats (Figure 7). Specifically, CER rats had a percent wet weight of 83% whereas the
PBS rats had approximately 65%. MET/CER rats experienced an 8% reduction in edema at 75%
when compared to CER rats. SAL/CER rats experienced a 10% reduction in edema at 83% when
compared to CER rats. Neither MET/CER nor SAL/CER rats displayed a significant difference
in percent wet weight from that of CER rats.
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2c. Histology (Mouse). Histological assessment of sections gathered from pancreatic tissue
demonstrates clear histological damage in all sections of animals treated with CER (including
MET/CER and SAL/CER) (Figure 8). This damage included severe edema, plasma membrane
blebbing, and pyknotic nuclei. PBS, MET, and SAL showed no cellular damage. Damage in the
pre-treated sections is thought to be the result of stress on the animals, as they received six
injections in a matter of six hours. This amount of stress alone might have cause the damage in
the pre-treated sections.
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V. Discussion
This study demonstrates that pre-treatment with the AMPK activators metformin and
salicylate can lessen the severity of the early stages of acute pancreatitis in in vivo models.
Although metformin and salicylate are able to lessen the pancreatitis responses by activating
AMPK, cerulein causes an increase in pathological responses despite being able to activate
AMPK. It has been shown that when cerulein activates AMPK, AMPK is translocated to an
unidentified Triton X-100 insoluble compartment in the acinar cell, preventing AMPK from
exerting its protective effects.[5] Now, a new set of questions arises: Do metformin and salicylate
prevent this translocation and, if so, how?
Three potential answers to this question are being considered. First, it is possible that
metformin and salicylate are directly preventing the translocation of AMPK. By altering the
conformation of one of the AMPK subunits, metformin and salicylate might prevent the
translocation of AMPK. A chaperonin might also play a role in this potential mechanism.
Second, cerulein might be stimulating additional pathways that move AMPK. Metformin and
salicylate might be preventing these pathways from translocating active AMPK. Third,
metformin and salicylate might be activating different AMPK proteins than cerulein, which
could explain why AMPK activated by cerulein translocates away while AMPK activated by
these drugs does not.
An important point to note is the difference between prophylactic and therapeutic
treatment. In this study, salicylate and metformin were considered to be prophylactic treatments,
or pre-treatments. Prophylactic treatments such as this one could be useful in patients with
hereditary pancreatitis.[9] Patients with hereditary pancreatitis often experience recurrent
problems and undergoing prophylactic treatments of salicylate and metformin in low doses could
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potentially be useful as a preventive measure. In addition, patients who undergo invasive
procedures such as Endoscopic Retrograde Cholangeopancreatography (ERCP) could benefit
from prophylactic treatment.[10] ERCP is used when a patient’s pancreatic or bile ducts are
narrowed or fully blocked. The procedure makes use of an endoscope and X-rays for treatment.
A major complication that frequently arises from this procedure is pancreatitis.[11] By
administering prophylactic treatments to patients prior to undergoing ERCP, post-ERCP
pancreatitis may be avoided. Future studies should also consider the therapeutic effect of
salicylate, metformin, and additional AMPK activating drugs.
It has also been discovered that different isoforms for each of the three AMPK subunits
exist in the acinar cell. For instance, the α subunit can exist as α1 or α2, the β subunit can exist as
β1 or β2, and the γ subunit can exist as γ1, γ2, or γ3 [12]. Theoretically, there are twelve possible
isoform combinations for the protein AMPK (ex. α1β1γ1, α1β2γ2, etc.). Drugs that target a
specific subunit of AMPK could be of greater therapeutic value if the abundance of each subunit
is better determined. The use of AMPK-α1 and AMPK-α2 knockout mice should also be
considered in future studies, as genetically reducing levels of AMPK in mice should confirm that
salicylate and metformin are acting through AMPK.
Since metformin and salicylate employ different mechanisms of action in activating
AMPK, it may of great importance to consider the combination of MET and SAL as a potential
prophylactic and therapeutic agent, as this combination may further reduce the severity of early
acute pancreatitis responses.
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